Answers are grounded in this paper and cite their sources.
This retrospective study assesses the effect of biopsy methods on prognosis in stage I endometrioid cancer, indicating limited impact on outcomes.
Background/Aim: Endometrial cancer is commonly diagnosed via endometrial biopsy, often performed alongside diagnostic hysteroscopy, a procedure raising concerns about tumor cell dissemination and recurrence, particularly during operative hysteroscopies. The aim of this study was to assess the impact of the diagnostic method on the prognosis of stage I endometrioid cancer. Patients and Methods: This retrospective bi-centric study (2010-2019) included patients with stage I endometrioid cancer, categorized into three groups according to the diagnostic method: “Blind Biopsy,” “Diagnostic Hysteroscopy,” and “Operative Hysteroscopy.” The primary endpoints were recurrence or death at three and five years following surgical treatment. Results: A total of 169 patients were included; 33 were lost to follow-up at three years. Among the remaining 136, 11 recurrences (8.1%) and six deaths (4.4%) were recorded. The “Operative Hysteroscopy” group had a recurrence rate of 10.4% (7/67), with no significant difference compared to the other groups (p=0.66). Recurrence-free survival at 3 years was 90.6% for the overall population and 89.6% for the “Operative Hysteroscopy” group (p=0.55). Conclusion: The biopsy diagnostic methods did not have a significant impact on the 3-year prognosis of patients with stage I endometrioid cancer.
No takes yet. Share an insight, caveat, or question.
Helms et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: